dapoxetine has been researched along with Neurally Mediated Faint in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aquilina, J; Kell, S; Modi, NB; Rivas, D | 1 |
| Aquilina, JW; DiBattiste, PM; Kowey, PR; Mudumbi, RV | 1 |
1 trial(s) available for dapoxetine and Neurally Mediated Faint
| Article | Year |
|---|---|
Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Area Under Curve; Benzylamines; Cross-Over Studies; Dizziness; Double-Blind Method; Half-Life; Headache; Hemodynamics; Humans; Hypotension, Orthostatic; Male; Middle Aged; Naphthalenes; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Syncope, Vasovagal; Tamsulosin | 2008 |
1 other study(ies) available for dapoxetine and Neurally Mediated Faint
| Article | Year |
|---|---|
Cardiovascular safety profile of dapoxetine during the premarketing evaluation.
Topics: Animals; Benzylamines; Cardiovascular System; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Naphthalenes; Selective Serotonin Reuptake Inhibitors; Syncope, Vasovagal | 2011 |